title: Recent trends in antibody-based oncologic imaging.
abstract: Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SERS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer.
authors: Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
authors: Sukhwinder
authors: S
authors: Kaur
authors: Ganesh
authors: G
authors: Venktaraman
authors: Maneesh
authors: M
authors: Jain
authors: Shantibhusan
authors: S
authors: Senapati
authors: Pradeep K
authors: PK
authors: Garg
authors: Surinder K
authors: SK
authors: Batra
mesh_terms: D000911:Antibodies, Monoclonal; D003952:Diagnostic Imaging / Q000639:trends*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009369:Neoplasms / Q000175:diagnosis*; D014055:Tomography, Emission-Computed
chemical_list: D000911:Antibodies, Monoclonal